Endeavor PMA complete
This article was originally published in The Gray Sheet
Executive Summary
Medtronic submits the final module of its PMA application for the Endeavor zotarolimus-eluting stent Nov. 16. The application includes data from 4,100 patients with up to three years of follow-up. The completed submission comes as first-generation Cypher and Taxus drug-eluting stents are under increased scrutiny for late stent thrombosis. Medtronic will join Johnson & Johnson/Cordis, Boston Scientific and other drug-eluting stent makers in presenting thrombosis data before an FDA panel next month (1"The Gray Sheet" Oct. 30, 2006, p. 5)...
You may also be interested in...
Companies Response To Thrombosis Data Differs; New Definition Unveiled
Boston Scientific and Johnson & Johnson/Cordis had markedly different responses to analyses reported last week at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. showing an increased risk of thrombosis from use of their drug-eluting stents (DES)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.